Zimmer Biomet Holdings, Inc. $ZBH Stock Holdings Boosted by Oak Thistle LLC

Oak Thistle LLC boosted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 413.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 16,393 shares of the medical equipment provider’s stock after purchasing an additional 13,201 shares during the quarter. Oak Thistle LLC’s holdings in Zimmer Biomet were worth $1,615,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ZBH. Cary Street Partners Investment Advisory LLC increased its stake in shares of Zimmer Biomet by 83.7% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 149 shares during the period. Headlands Technologies LLC acquired a new position in shares of Zimmer Biomet during the second quarter worth approximately $37,000. CoreFirst Bank & Trust acquired a new position in shares of Zimmer Biomet during the second quarter worth approximately $38,000. Hilltop National Bank bought a new position in Zimmer Biomet in the 2nd quarter worth approximately $42,000. Finally, True Wealth Design LLC increased its position in Zimmer Biomet by 875.0% in the 2nd quarter. True Wealth Design LLC now owns 468 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 420 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Barclays reduced their price target on Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating for the company in a research report on Wednesday, November 5th. Wall Street Zen downgraded shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Sunday, November 16th. Johnson Rice set a $112.00 target price on shares of Zimmer Biomet in a research report on Wednesday, November 5th. BTIG Research dropped their price target on shares of Zimmer Biomet from $122.00 to $112.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Finally, Robert W. Baird reaffirmed a “neutral” rating and issued a $100.00 price target (down from $117.00) on shares of Zimmer Biomet in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $107.50.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $91.53 on Thursday. The company has a quick ratio of 1.39, a current ratio of 2.43 and a debt-to-equity ratio of 0.59. The business’s 50-day moving average price is $95.21 and its 200 day moving average price is $96.70. Zimmer Biomet Holdings, Inc. has a 52-week low of $85.33 and a 52-week high of $114.44. The firm has a market cap of $18.14 billion, a P/E ratio of 22.66, a PEG ratio of 2.39 and a beta of 0.61.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. The company had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. Zimmer Biomet’s revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the company earned $1.74 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Tuesday, December 30th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.76%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.